PLX

Business Context and Reporting Period

Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Protalix is a clinical-stage biopharmaceutical company operating through its wholly-owned subsidiary, Protalix Ltd. The company focuses on developing recombinant therapeutic proteins using a proprietary plant cell system. Its lead product candidate, prGCD, is a plant-derived enzyme for the treatment of Gaucher Disease. The company completed a Phase I clinical trial in June 2006 and received FDA approval in April 2007 to initiate a Phase III trial, expected to commence in mid-2007.

Key Financial Metrics

Liquidity: As of March 31, 2007, the company held $24.9 million in cash and cash equivalents. Management believes these resources are sufficient to fund operations for at least the next 18 months.

Material Changes vs. Prior Period

• Revenue: The company recorded $830,000 in revenue for Q1 2007, compared to zero in Q1 2006. This revenue is primarily attributed to grants received from the Office of the Chief Scientist (OCS).
• Operating Expenses:
  • R&D Expenses: Increased 104% to $2.5 million, driven by a $1 million increase in salaries, consulting, and materials. This was partially offset by an increase in OCS grants from $373,000 to $738,000.
  • G&A Expenses: Increased 156% to $2.0 million, primarily due to a $718,000 increase in share-based compensation resulting from stock option awards granted in late 2006.
• Net Loss: Widened to $3.45 million from $1.56 million in the prior year quarter, reflecting the significant increase in operating costs.
• Cash Position: Cash balances increased significantly from $3.4 million to $24.9 million, largely due to $12.9 million in financing proceeds from the exercise of warrants in January 2007.

Outlook, Risks, and Management Commentary

Outlook: Management expects to incur substantial operating losses for the foreseeable future as R&D expenses increase with the advancement of clinical trials, specifically the upcoming Phase III trial for prGCD. The company anticipates needing additional financing to fund future development and potential new manufacturing facilities.

Risks and Contingencies:

• Regulatory Approval: Success is dependent on obtaining FDA and foreign regulatory approvals, which cannot be assured.
• Capital Requirements: The company has no approved products and relies on external financing (equity, debt, or collaborations) to continue operations.
• Currency Risk: Approximately 50% of costs are incurred in New Israeli Shekels (NIS). A decline in the U.S. dollar relative to the NIS would increase operating costs.
• Development Risks: Risks include delays in clinical trials, patient enrollment issues, and potential rejection of regulatory applications.

Unusual Items: The financial statements reflect a recapitalization following a reverse merger with Protalix Ltd. effective December 31, 2006. The historical financial statements reflect the operations of Protalix Ltd.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $24.9 million cash balance against the projected 18-month burn rate, considering the high cost of Phase III trials.
• Revenue Quality: Confirm the nature of the $830,000 revenue, as it appears to be grant-based rather than product sales, indicating a lack of commercial product revenue.
• Dilution Risk: Review the impact of the 3.9 million shares issued via warrant exercise in January 2007 and potential future equity offerings required to fund operations.
• Currency Exposure: Assess the impact of NIS fluctuations on the 50% of expenses incurred in Israel.
• Clinical Milestones: Monitor the initiation of the Phase III prGCD trial in mid-2007 as a critical catalyst for future valuation.